- Home
- ALNY vs NXPI Comparison
ALNY vs NXPI Comparison
Compare ALNY & NXPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- NXPI
- Stock Information
- Founded
- ALNY 2002
- NXPI 2006
- Country
- ALNY United States
- NXPI Netherlands
- Employees
- ALNY N/A
- NXPI N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- NXPI Semiconductors
- Sector
- ALNY Health Care
- NXPI Technology
- Exchange
- ALNY Nasdaq
- NXPI Nasdaq
- Market Cap
- ALNY 59.6B
- NXPI 59.2B
- IPO Year
- ALNY 2004
- NXPI 2010
- Fundamental
- Price
- ALNY $450.56
- NXPI $226.44
- Analyst Decision
- ALNY Strong Buy
- NXPI Strong Buy
- Analyst Count
- ALNY 29
- NXPI 20
- Target Price
- ALNY $435.04
- NXPI $250.30
- AVG Volume (30 Days)
- ALNY 1.1M
- NXPI 2.2M
- Earning Date
- ALNY 10-30-2025
- NXPI 11-03-2025
- Dividend Yield
- ALNY N/A
- NXPI 1.83%
- EPS Growth
- ALNY N/A
- NXPI N/A
- EPS
- ALNY N/A
- NXPI 8.39
- Revenue
- ALNY $2,461,963,000.00
- NXPI $12,122,000,000.00
- Revenue This Year
- ALNY $58.79
- NXPI N/A
- Revenue Next Year
- ALNY $39.75
- NXPI $9.59
- P/E Ratio
- ALNY N/A
- NXPI $26.33
- Revenue Growth
- ALNY 5.01
- NXPI N/A
- 52 Week Low
- ALNY $205.87
- NXPI $148.09
- 52 Week High
- ALNY $484.21
- NXPI $256.62
- Technical
- Relative Strength Index (RSI)
- ALNY 53.89
- NXPI 53.23
- Support Level
- ALNY $454.51
- NXPI $215.65
- Resistance Level
- ALNY $467.28
- NXPI $223.54
- Average True Range (ATR)
- ALNY 12.99
- NXPI 6.14
- MACD
- ALNY -4.42
- NXPI -0.79
- Stochastic Oscillator
- ALNY 21.20
- NXPI 49.89
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About NXPI NXP Semiconductors N.V.
NXP Semiconductors is a leading supplier of high-performance mixed-signal products. The firm acquired Freescale Semiconductor in 2015 and now has significant market share in the automotive market, where it supplies microcontrollers and analog chips into automotive clusters, powertrains, infotainment systems, and radars. NXP Semiconductors also serves industrial and Internet of Things, mobile, and communications infrastructure.